MedCity News January 15, 2025
Revenue for the blockbuster Eli Lilly drugs Mounjaro and Zepbound continues to grow, but not as much as expected. At the J.P. Morgan Healthcare Conference, Lilly CEO David Ricks explained why the company revised downward its projections for fourth quarter 2024 revenue.
Only in the crazy sector of metabolic medicines can 32% revenue growth be considered a disappointment. That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors.
Lilly on Tuesday revised its revenue guidance for the fourth quarter to about $13.5 billion, which is about $400 million less than the company’s previous revenue projection. The company attributed the...
Today's Sponsors
Today's Sponsor